Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.

Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.

2.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

3.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.

Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.

PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.

4.

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.

Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS.

Clin Cancer Res. 2009 Oct 1;15(19):6148-57. doi: 10.1158/1078-0432.CCR-09-1039. Epub 2009 Sep 29.

5.

In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.

Chu SH, Karri S, Ma YB, Feng DF, Li ZQ.

Neuro Oncol. 2013 Jul;15(7):880-90. doi: 10.1093/neuonc/not030. Epub 2013 Mar 21.

6.

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.

Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D.

Clin Cancer Res. 2009 May 1;15(9):3050-7. doi: 10.1158/1078-0432.CCR-08-2954. Epub 2009 Apr 14.

7.
8.

Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.

Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG.

Clin Cancer Res. 2011 Apr 1;17(7):1807-14. doi: 10.1158/1078-0432.CCR-10-1276. Epub 2011 Feb 15.

9.

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.

10.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

11.

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.

Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, Denk H.

Mol Cancer. 2010 Mar 4;9:49. doi: 10.1186/1476-4598-9-49.

12.

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.

Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2008 Feb 1;14(3):931-8. doi: 10.1158/1078-0432.CCR-07-1856.

13.

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Lee JH, Choy ML, Ngo L, Foster SS, Marks PA.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.

14.

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA.

Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.

15.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
16.

The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.

Sampson ER, Amin V, Schwarz EM, O'Keefe RJ, Rosier RN.

J Orthop Res. 2011 Apr;29(4):623-32. doi: 10.1002/jor.21274. Epub 2010 Oct 18.

17.

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH.

Clin Cancer Res. 2011 Nov 1;17(21):6754-65. doi: 10.1158/1078-0432.CCR-11-0544. Epub 2011 Oct 25.

18.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

Clin Cancer Res. 2012 Feb 15;18(4):1051-62. doi: 10.1158/1078-0432.CCR-11-1507. Epub 2011 Dec 15.

19.

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jan 15;15(2):607-12. doi: 10.1158/1078-0432.CCR-08-2079.

20.

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK.

Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2.

PMID:
20119866
Items per page

Supplemental Content

Write to the Help Desk